Revolution Medicines Inc Warrant
RVMDW
22 hedge funds and large institutions have $1.89M invested in Revolution Medicines Inc Warrant in 2023 Q4 according to their latest regulatory filings, with 22 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
4.5% more ownership
Funds ownership: 0% → 4.5% (+4.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
+$602K |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$272K |
| 3 |
Walleye Capital
New York
|
+$266K |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$223K |
| 5 |
SCM
Soros Capital Management
New York
|
+$163K |
Top Sellers
RVMDW Hedge Fund Activity: Q4 2023 in Review
22 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Revolution Medicines Inc Warrant (RVMDW) for Q4 2023, worth a combined $1.89M.
Buyers outnumbered sellers: 22 funds opened new RVMDW positions and 0 closed out — a net gain of 22 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was D.E. Shaw & Co, opening a new position worth an estimated $602K.
- 22 institutional investors held Revolution Medicines Inc Warrant (RVMDW) as of Q4 2023, up from 0 in Q3 2023.
- Funds reported $1.89M of Revolution Medicines Inc Warrant stock for Q4 2023.
- 22 funds opened new Revolution Medicines Inc Warrant positions in Q4 2023 and 0 closed out, a net change of +22 holders.
- The largest Revolution Medicines Inc Warrant buyer in Q4 2023 was D.E. Shaw & Co, an estimated $602K added.
Based on aggregated 13F filings for Q4 2023.